Related Experiment Video
Updated: Oct 27, 2025

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
Comparability: what we can learn from the review of advanced therapy medicinal products
Alexis Cockroft1, Alison Wilson2
1Lex Regulatory Ltd, Arrington, Royston, SG8 0BD, UK.
Abstract:
Publicly available summaries from Marketing Authorization Applications for gene and cell therapy products (advanced therapies) were evaluated to explore data expectations for product characteristics pre and post changes (comparability). Public assessment reports were used to analyze trends in information requests from regulators concerning comparability from current commercial advanced therapies. In the analysis, 12 products approved in the USA and EU were included. Inadequacies were highlighted for comparability data (six products); additional information requests (five products) and major objections were identified relating to comparability (two products, EU). Postapproval authorization obligations were imposed for six products. Comparability data are essential component for regulatory applications and public assessment reports provide a valuable source of insight into regulators' expectations.
Related Concept Videos
Drug Products: Biologics, Biosimilars and Interchangeables
Bioequivalence of Drugs: Drugs with Multiple Indications
Bioequivalence: Overview
Pharmaceutical Equivalents
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence

